Movement Disorders

Cover image for Movement Disorders

Supplement: Selegiline in Parkinson' Disease: An Update

1993

Volume 8, Issue S1

Pages fmi–fmi, v–v, S1–S44

  1. Masthead

    1. Top of page
    2. Masthead
    3. Articles
    1. Masthead (page fmi)

      Article first published online: 12 OCT 2004 | DOI: 10.1002/mds.870080501

  2. Articles

    1. Top of page
    2. Masthead
    3. Articles
    1. Preface (page v)

      P. Riederer and U. K. Rinne

      Article first published online: 12 OCT 2004 | DOI: 10.1002/mds.870080502

    2. Neurotoxins and monoamine oxidase inhibition: New aspects (pages S14–S19)

      Prof. K. T. Finnegan

      Article first published online: 12 OCT 2004 | DOI: 10.1002/mds.870080505

    3. Nigral degeneration in parkinson's disease (pages S31–S35)

      Dr. J. O. Rinne

      Article first published online: 12 OCT 2004 | DOI: 10.1002/mds.870080507

    4. Symptomatic effect of selegiline in de novo parkinsonian patients (pages S36–S40)

      Prof. H. Allain, P. Pollak and H. C. Neukirch

      Article first published online: 12 OCT 2004 | DOI: 10.1002/mds.870080508

    5. Selegiline in de novo parkinsonian patients: The finnish study (pages S41–S44)

      Prof. V. V. Myllylä, K. A. Sotaniemi, J. A. Vuorinen and E. H. Heinonen

      Article first published online: 12 OCT 2004 | DOI: 10.1002/mds.870080509

SEARCH

SEARCH BY CITATION